MarginsXMarginsX
Home › Markets › Health Care › KYMR

Kymera Therapeutics Inc. (KYMR)

KYMR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$125.85
-1.35% on the day
Market cap
$10.7B
Large cap
Revenue · 2025
$39.2M
-16.7% on 2024
Net income · 2025
-$311.4M
-794.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1815442/000119312526073395/0001193125-26-073395-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerKYMR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001815442
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$39.2M
Net income-$311.4M
Operating income-$349.4M
Net margin-794.0%
Operating margin-891.1%
Revenue growth-16.7%
Cash$357.0M
Total assets$1.7B
P/E (computed)Net income was not positive
P/S (computed)274.0×

Warning signs

Cash runway
15.6 months
$373.4M cash at September 30, 2026
Share count, 1 year
+18.7%
2025-10-31 to 2026-10-23 · +53.9% over 3 years
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
-$302.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-29
Cash and burn$373.4M cash; operating cash flow -$71.9M a quarter.Report 2026-09-30
Shares outstanding85,371,397 (2026-10-23); 71,949,027 a year earlier; 55,487,373 three years earlier.Cover page 2026-10-23
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-02-26
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $172.5M, sold $475.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$132.0M-$77.9M$373.4MNo debt tags$102.2M10-Q 2026-10-29
Q2 2026
2026-06-30
$65.0M-$61.2M-$54.1M$124.5MNo debt tags$105.0M10-Q 2026-08-05
Q1 2026
2026-03-31
$34.4M-$69.2M-$88.8M$144.1MNo debt tags$51.5M10-Q 2026-04-30
Q4 2025
2025-12-31
$2.9M-$87.0M-$66.7M$357.0MNo debt tags$39.2M10-K 2026-02-26
Q3 2025
2025-09-30
$2.8M-$82.2M-$27.1M$112.9MNo debt tags$43.7M10-Q 2026-10-29
Q2 2025
2025-06-30
$11.5M-$76.6M-$59.9M$335.8MNo debt tags$44.7M10-Q 2026-08-05
Q1 2025
2025-03-31
$22.1M-$65.6M-$79.2M$90.0MNo debt tags$58.9M10-Q 2026-04-30
Q4 2024
2024-12-31
$7.4M-$70.8M-$61.8M$120.3MNo debt tags$47.1M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-02-26
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-10-29
Latest current report8-K2026-10-29
Latest proxyDEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 647 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.2%
1 month+19.6%
3 months+11.5%
Year to date+64.0%
1 year+100.5%
From 52-week high-8.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
HALOHalozyme Therapeutics Inc.$96.50-3.76%$11.0B
RGENRepligen Corporation$162.78-2.99%$10.4B
QGENQiagen N.V. Common Shares$49.81-0.16%$10.3B
TECHBio-Techne Corp$72.79-0.01%$11.4B
PCVXVaxcyte Inc.$61.61-2.78%$9.8B
KRYSKrystal Biotech Inc.$297.90-2.40%$8.8B
CGONCG Oncology Inc.$84.78+13.95%$7.6B
EXELExelixis Inc.$67.10-2.75%$16.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier